Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Abbott decides to...

    Abbott decides to withdraw 2 stent types from India

    Written by supriya kashyap kashyap Published On 2017-04-22T09:47:36+05:30  |  Updated On 16 Aug 2021 2:33 PM IST
    New Delhi : Healthcare major Abbott has decided to withdraw two types of stents from the Indian market in the wake of drug price regulator National Pharmaceutical Pricing Authority's (NPPA's) move to cap the prices.

    The company has applied to the NPPA seeking to withdraw two kinds of stents.


    These are Alpine drug-eluting stent and Absorb dissolving stent.



    An Abbott spokesperson said that following the NPPA's price ceiling decision, it "examined and re-examined" whether there is a sustainable way to make available two of the latest stent technologies in India.

    The company took into consideration Alpine drug-eluting and the Absorb dissolving stents' higher manufacturing costs and other associated costs.


    "We have determined it is not sustainable, and we have applied to the NPPA to withdraw these two stents," the spokesperson told PTI in an e-mailed statement.


    The company said that presently, only a very small percentage of patients in India receive Alpine and Absorb stents.


    "While we are aligned with the government's intent for broad access to care, we're disappointed that the NPPA concluded there is no differentiation in coronary stent technology," the company noted.


    According to Abbott, it would continue to make available all other XIENCE coronary stent products within the ceiling price set by the NPPA.


    "Alpine and Absorb will continue to remain available while the government reviews our application. There is no shortage of Abbott stents," it added.

    AbbottAbsorb stentsAlpineCoronary StentsNational Pharmaceutical Pricing AuthorityNPPAXIENCE
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok